You are invited to the OUHSC Department of Pediatrics Grand Rounds

Course No. 19D06

Wednesday, March 6, 2019

12:15-1:15pm

**\* \* \*Samis Education Center \* \* \***

**Rainbolt Family Auditorium**

**“*The evolution of prognostic factors in neuroblastoma (NB),***

***and their changing roles in risk stratification to assign intensity of therapy*”**

- - - - - - - - - - - - - - - - - - - -

Presented by:

**Wendy London, PhD**

Associate Professor of Pediatrics

Dana-Farber/Boston Children’s Cancer and Blood Disorder Center

Harvard Medical School

***CHF Nitschke-Kaskaske Visiting Professor***

Invited by:  Pediatric Hematology/Oncology

OUHSC Department of Pediatrics

**Learning Objectives:** Upon completion of this session, participants will improve their competence and performance by being able to:

1. Name and describe factors prognostic of outcome (event-free survival and overall survival) in neuroblastoma patients who: a) are newly diagnosed; or, b) have relapsed/progressing disease
2. Describe how neuroblastoma prognostic factors are identified
3. Describe how neuroblastoma prognostic factors are applied to create a risk stratification, which in turn is used to assign treatment intensity

**Professional Practice Gap:**

The ideal practice for treatment children with neuroblastoma is that we would be able to precisely match tumor and host “omics” with treatments that result in cure.

Gap 1: Occasionally, a treating physician will have appropriate reasons to deviate from the level of treatment intensity specified by the risk group.

Gap 2: Most of the NB prognostic factors are surrogates.  In an ideal world, we would know all the genetic mutations that drive the occurrence and progression of NB in a given patient, in order to provide targeted, curative therapy.  But we’re not there yet.

If you wish to view video tapes of past GR, go to <http://mediasite.ouhsc.edu/Mediasite/Catalog/catalogs/PEDGR>

Note: We do not have permission from all presenters to videotape their presentations.

**A list of upcoming Pediatric GR topics can be found at:** <https://www.oumedicine.com/department-of-pediatrics/research-and-education/grand-rounds>

**Accreditation Statement:** The University of Oklahoma College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Oklahoma College of Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit™.*  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Conflict Resolution Statement:** The University of Oklahoma College of Medicine, Office of Continuing Professional Development has reviewed this activity’s speaker and planner disclosures and resolved all identified conflicts of interest, if applicable.

**Nondiscrimination Statement:**

The University of Oklahoma, in compliance with all applicable federal and state laws and regulations, does not discriminate on the basis of race, color, national origin, sex, sexual orientation, genetic information, gender identity, gender expression, age, religion, disability, political beliefs, or status as a veteran in any of its policies, practices or procedures. This includes, but is not limited to: admissions, employment, financial aid and educational services. Inquiries regarding non-discrimination policies may be directed to: Bobby J. Mason, Institutional Equity Officer, (405) 325-3546, bjm@ou.edu, or visit [www.ou.edu/eoo.](http://www.ou.edu/eoo.html)

**Accommodation Statement:** For accommodations, please contact Alix Darden, PhD, MEd at 405-271-4401 or [alix-darden@ouhsc.edu](alix-darden%40ouhsc.edu).

**Disclaimer Statement:** Statements, opinions and results of studies contained in the program are those of the presenters and authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability.

Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.

**Policy on Faculty and Presenter Disclosure:** It is the policy of the University of Oklahoma College of Medicine that the faculty and presenters disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also discloses discussions of unlabeled/ unapproved uses of drugs or devices during their presentation(s).

**Acknowledgement of Commercial and In-Kind Support:** This activity received no commercial or in-kind support.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |
| **Disclosure & Resolution  Report**The University of Oklahoma College of Medicine and the Irwin H. Brown Office of Continuing Professional Development must ensure balance, independence, objectivity and scientific rigor in all its activities.  We have implemented a process where everyone who is in a position to control the content of an educational activity has disclosed to us all relevant financial relationships with any commercial interest. In addition, should it be determined that a conflict of interest exists as a result of a financial relationship one may have, this will be resolved prior to the activity. This policy is designed to provide the target audience with an opportunity to review any affiliations between the CME organizers and presenters and supporting organizations for the purpose of determining the potential presence of bias or influence over educational content. The following is a summary of this activities disclosure information. |   |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Nature of Relevant Financial Relationship** |   |   |
| **Role** | **First Name** | **Last Name** | **Commercial Interest** |  | **What was received?** | **For what role?** |   |   |
| Course Director/ Moderator | Alix | Darden, PhD, MEd | I have no relevant financial relationships or affiliations with commercial interests to disclose. |   |   |
| Co-Course Director | Stephanie | DeLeon, MD | I have no relevant financial relationships or affiliations with commercial interests to disclose. |   |   |
| Course Contact | Cindy | Dibler | I have no relevant financial relationships or affiliations with commercial interests to disclose. |   |   |
| Planning Member/Moderator | Mo | Gessouroun, MD | I have no relevant financial relationships or affiliations with commercial interests to disclose. |   |   |
| Planning Member – Resident | Colleen | Parrish, MD | I have no relevant financial relationships or affiliations with commercial interests to disclose. |   |   |
| Planning Member/Moderator | Muhammad A. | Altaf, MD | I have no relevant financial relationships or affiliations with commercial interests to disclose. |   |   |
| Planning Member/ Moderator/Speaker | Ami | Bax, MD | I have no relevant financial relationships or affiliations with commercial interests to disclose. |   |   |
| Planning Member/Moderator | Amanda | Bogie, MD | I have no relevant financial relationships or affiliations with commercial interests to disclose. |   |   |
| Planning Member/Moderator | Steven D. | Chernausek, MD | Novo Nordisk | Consulting Fee | Consultant |   |   |
| Planner/Moderator: The conflict was resolved by Dr. Chernausek agreeing to recuse herself from planning content in the conflicted area and limiting her role to the introduction of presenters, fielding questions and moderating the flow of discussion between participants and presenters. |   |   |
| Planning Member/Moderator | Paul | Darden, MD | I have no relevant financial relationships or affiliations with commercial interests to disclose. |   |   |
| Planning Member/Moderator | Jennifer | Baker, MD | I have no relevant financial relationships or affiliations with commercial interests to disclose. |   |   |
| Planning Member/Moderator | Pascale | Lane, MD | I have no relevant financial relationships or affiliations with commercial interests to disclose. |   |   |
| Planning Member/Moderator | Amy | Middleman, MD, MSEd, MPH | Up to Date | Royalties | Section Editor/Author |   |   |
| Planner/Moderator: The conflict was resolved by Dr. Middleman agreeing to recuse herself from planning content in the conflicted area and limiting her role to the introduction of presenters, fielding questions and moderating the flow of discussion between participants and presenters. |   |
| Planning Member/Moderator | William  | Meyer, MD | I have no relevant financial relationships or affiliations with commercial interests to disclose. |   |   |
| Planning Member/Moderator | Edward D. | Overholt, MD | I have no relevant financial relationships or affiliations with commercial interests to disclose. |   |   |
| Planning Member/Moderator | Kris | Sekar, MD | I have no relevant financial relationships or affiliations with commercial interests to disclose. |   |   |
| Planning Member/Moderator | Robert C. | Welliver, Sr., MD | Vindico Medical Education | Speaker Fees | Speaker |   |   |
| Planner/Moderator: The conflict was resolved by Dr. Welliver agreeing to recuse himself from planning content in the conflicted area and limiting his role to the introduction of presenters, fielding questions and moderating the flow of discussion between participants and presenters. |   |   |
| Speaker | Wendy | London, PhD | United Therapeutics Corp. and ArQule, Inc. | Consulting Fee | Consultant |   |   |
| Speaker: The conflict was resolved by Dr. London agreeing to refrain from making recommendations on topics in which the conflicts exists and agreeing that the presentation will not include discussion of any product or services from the listed commercial interests.Dr. London will be discussing experimental or off-label drugs and therapies that have not been approved by the FDA. |  |   |